Allarity announces VA-funded Phase 2 trial of stenoparib + temozolomide in recurrent SCLC

Allarity Therapeutics, Inc.

Phase 2 trial of stenoparib (dual PARP/Wnt inhibitor) plus temozolomide for recurrent SCLC, fully funded by VA.
Trial expects ~65 patients across 11 VA medical centers; initial safety lead-in to set recommended dose.
Cash position supports operations into 2026; VA funding does not affect financial outlook or share repurchase plan.
Stenoparib crosses blood-brain barrier, potentially treating brain metastases common in SCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.